Literature DB >> 12928404

Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.

Marc Tritel1, Amy M Stoddard, Barbara J Flynn, Patricia A Darrah, Chang-you Wu, Ulrike Wille, Javeed A Shah, Yue Huang, Ling Xu, Michael R Betts, Gary J Nabel, Robert A Seder.   

Abstract

A prophylactic vaccine for HIV-1 will probably require the induction and maintenance of both humoral and cellular immunity. One current strategy to achieve such long term immune responses is a prime-boost vaccination approach using a DNA priming inoculation, followed by recombinant viral boost. In this report we use a novel prime-boost approach in which the priming injections consist of recombinant HIV-1 Gag protein mixed with cytosine phosphate guanosine oligodeoxynucleotide (CpG ODN), followed by recombinant adenoviral boost expressing HIV-1 Gag. Analysis of the immune responses indicates that HIV-1 Gag protein plus CpG ODN immunization alone induces potent humoral as well as Th1 and CD8+ T cell responses. Boosting with recombinant adenovirus strikingly enhances CD8+, but not Th1, T cell responses, resulting in CD8+ T cell responses far greater in magnitude than Th1 responses. Furthermore, the Th1 and CD8+ T cell responses following prime-boost immunization were seen in both lymphoid and peripheral mucosal organs and were sustained over several months. Together, these data suggest a new immunization approach for elicitation of long term humoral and cellular immune responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12928404     DOI: 10.4049/jimmunol.171.5.2538

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Altered function in CD8+ T cells following paramyxovirus infection of the respiratory tract.

Authors:  Peter M Gray; Subhashini Arimilli; Ellen M Palmer; Griffith D Parks; Martha A Alexander-Miller
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 2.  Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development.

Authors:  E G Rhee; D H Barouch
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

3.  Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT.

Authors:  James N Kochenderfer; Jessica L Simpson; Christopher D Chien; Ronald E Gress
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

4.  HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates.

Authors:  Ulrike Wille-Reece; Barbara J Flynn; Karin Loré; Richard A Koup; Ross M Kedl; Joseph J Mattapallil; Walter R Weiss; Mario Roederer; Robert A Seder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-11       Impact factor: 11.205

5.  Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity.

Authors:  Jennifer A McWilliams; Phillip J Sanchez; Catherine Haluszczak; Laurent Gapin; Ross M Kedl
Journal:  Vaccine       Date:  2009-12-06       Impact factor: 3.641

6.  Myd88 is required for an antibody response to retroviral infection.

Authors:  Edward P Browne; Dan R Littman
Journal:  PLoS Pathog       Date:  2009-02-13       Impact factor: 6.823

Review 7.  Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.

Authors:  L Jean Patterson; Marjorie Robert-Guroff
Journal:  Expert Opin Biol Ther       Date:  2008-09       Impact factor: 4.388

8.  Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection.

Authors:  Vanitha S Raman; Joanne O'Donnell; H Remy Bailor; Wakako Goto; Ramanuj Lahiri; Thomas P Gillis; Steven G Reed; Malcolm S Duthie
Journal:  Infect Immun       Date:  2009-09-28       Impact factor: 3.441

9.  A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection.

Authors:  Kejian Yang; Barbara J Whalen; Rebecca S Tirabassi; Liisa K Selin; Tatyana S Levchenko; Vladimir P Torchilin; Edward H Kislauskis; Dennis L Guberski
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

10.  Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.

Authors:  Igor M Belyakov; Jeffrey D Ahlers; Gary J Nabel; Bernard Moss; Jay A Berzofsky
Journal:  Virology       Date:  2008-09-14       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.